With 14 new product launches in major markets since 2009 and a group of core growth products Janssen is now the fastest growing of the top 10 pharmaceutical companies globally. In 2013, sales registered a 10.9% growth in comparison to 2012. In the first quarter of 2014, sales incremented 10.8% in comparison with the same period of the previous year. Great part of our growth is due to medications introduced since 2009; these products represented a 17% of the 2012 sales and they are expected to represent 50% of sales for 2017. And there is more to come. Our productivity in regards to Research and Development duplicated between 2009 and 2012. We have an industry leading pipeline of differentiated products, as well as the possibility of submitting more than 10 new requests for product approval and 25 significant extensions of the brand line for 2017.     

With a focus on transformational innovation and best-in-class commercial capabilities, we expect to continue to make significant contributions to global human health and deliver strong business results for years to come.